LCNDG Rapid Review: Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer

Source: London Cancer New Drugs Group Area: Evidence > Drug Specific Reviews BOLERO-2 is a high quality trial which showed that the combination regimen was associated with a 4.1-6.5 month increase in median progression free survival compared with exemestane alone. The trial was not powered to assess impact on overall survival and at present that data are immature.   The benefit described was seen in a population of women with fairly advanced disease - over 50% had received 3 or more previous lines of therapy, over 80% had received two or more lines of treatment and only 20% had just received one line of treatment. Similarly 56% of patients had visceral involvement and 76% had bone metastases at the time of recruitment.   The combination regimen was associated with an increased incidence of serious adverse events and about 10% more patients that receive this regimen will develop a grade 3/4 adverse event than if they received single-agent exemestane.   There are NICE approved treatments available for this group of patients. ...
Source: NeLM - Drug Specific Reviews - Category: Drugs & Pharmacology Source Type: news